Patra Pritish Chandra, Rainchwar Sujay, Singh Reema, Bhatia Niharika, Bhatnagar Sakshi, Palatty Roy J, Tikare Nakul, Panda Tribikram, Sheth Vipul Sharad, Agrawal Narendra, Halder Rohan, Bhurani Dinesh
Department of Hematology, IMS & SUM Hospital, Bhubaneshwar, India.
Shashwat Hemato-Onco Associates, Rajkot, Gujarat, India.
Ann Hematol. 2025 Apr;104(4):2483-2493. doi: 10.1007/s00277-025-06350-w. Epub 2025 Apr 15.
Chronic myeloid leukemia in the blast phase (BP-CML) remains challenging despite advancements in tyrosine kinase inhibitors (TKIs). This study retrospectively assessed BP-CML patients who underwent allogeneic stem cell transplantation (allo-SCT) from June 2009 to December 2022. Thirty-three patients were included and the median age was 41 years, with a predominantly male cohort. Myeloablative conditioning and peripheral blood stem cells were used in the majority of the patients. The estimated 2-year overall survival (OS) was 48.3% of the cohort. Relapse occurred in 48.5% of patients, typically within 3 months post-transplant. Post-transplant TKI maintenance showed a significant association with improved OS (p-value = 0.001). The study highlights the need for early intervention and optimized post-transplant maintenance to improve outcomes.
尽管酪氨酸激酶抑制剂（TKIs）取得了进展，但急变期慢性髓性白血病（BP-CML）仍然具有挑战性。本研究回顾性评估了2009年6月至2022年12月期间接受异基因干细胞移植（allo-SCT）的BP-CML患者。纳入了33例患者，中位年龄为41岁，以男性队列为主。大多数患者采用了清髓性预处理和外周血干细胞。该队列的估计2年总生存率（OS）为48.3%。48.5%的患者发生复发，通常在移植后3个月内。移植后TKI维持治疗与OS改善显著相关（p值=0.001）。该研究强调了早期干预和优化移植后维持治疗以改善结局的必要性。
